The cytokine and chemokine response elicited by heat-treated amphotericin B (HT-AmB) was compared with that of untreated amphotericin B (AmB-DOC) in the human monocyte cell line THP-1. AmB-DOC produced dose-dependent increases in interleukin (IL)-1β, IL-1α, tumour necrosis factor-α, macrophage inflammatory protein (MIP)-1α and MIP-1β at 2 h. HT-AmB induced cytokine and chemokine production at a lower level than those observed with corresponding concentrations of AmB-DOC, while retaining antifungal activity. These results indicate that heat treatment of amphotericin B may prove to be a cost-effective approach to improving the therapeutic index of this antifungal agent.
Introduction
Amphotericin B is a polyene antifungal antibiotic with activity against a number of pathogenic fungi. 1 Treatment of the amphotericin B deoxycholate micellar formulation by heating to 70°C for 20 min produces a 'superaggregated' form of amphotericin B. [2] [3] [4] [5] This novel formulation has been associated with less toxicity against mammalian cells while retaining antifungal activity both in vitro and in vivo. [2] [3] [4] Given the potential importance of the immunomodulatory properties of amphotericin B in both the toxicity and activity of this drug, we wished to determine whether heat-treated amphotericin B (HT-AmB) would elicit an attenuated cytokine and chemokine response in human monocytes compared with untreated amphotericin B.
Materials and methods

Reagents and cell culture
The deoxycholate salt of amphotericin B (AmB-DOC) was obtained from Bristol-Myers Squibb (New York, NY, USA).
RPMI 1640 medium was obtained from Sigma (St Louis, MO, USA). Low-endotoxin fetal bovine serum was purchased from Summit Biotech (Fort Collins, CO, USA) and Gibco-BRL/Invitrogen (Carlsbad, CA, USA). The human mononuclear cell line THP-1 (ATCC TIB 202) was cultured as described previously. 6 AmB-DOC was reconstituted in sterile water according to the manufacturer's directions. Heat treatment was carried out as described previously. 5 Amphotericin B concentrations >10 µg/mL have been associated with low cell viability. 6 Therefore, concentrations from 0.625 to 10 µg/mL were used in this study. Cell viability was assessed by erythrosin B exclusion, as described previously. 6 In vitro antifungal activity 
Cytokine and chemokine measurements
Tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-1α, IL-1 receptor antagonist (Ra), macrophage inflammatory protein (MIP)-1α, MIP-1β and monocyte chemoattractant protein (MCP)-1 concentrations were determined with commercial ELISA kits (R&D Systems, Minneapolis, MN, USA). After exposure to experimental conditions for 2 h supernatants were collected and stored at -70°C until assay. Duplicate measurements were made for each of two wells from three individual experiments.
Statistics and presentation of data
Data are expressed as means ± S.E.M. Data sets were compared by use of Student's two-tailed, paired t-test. The Bonferroni correction was used for multiple comparisons. Significance was considered to be achieved when the P value was <0.05.
Results
Heat treatment of amphotericin B alters its toxicity against THP-1 cells
Viability of THP-1 cells was unchanged (virtually 100% viable) after a 2 h exposure to AmB-DOC concentrations up to 2.5 µg/mL. Higher concentrations produced dose-dependent cell death. In contrast, viability was unchanged (100%) at HT-AmB concentrations up to 10 µg/mL.
Heat treatment of amphotericin B does not alter its activity against C. albicans
No difference in antifungal activity against Candida species was observed between the two preparations. As shown in Table 1 , the IC 50 and MIC for both preparations tested in RPMI were virtually identical.
Heat treatment of amphotericin B attenuates cytokine and chemokine production
AmB-DOC at concentrations up to 5 µg/mL produced dosedependent increases in IL-1β, TNF-α, MIP-1α and MIP-1β. A dose-dependent response was observed for IL-1α at AmB-DOC concentrations up to 2.5 µg/mL. Loss of dosedependent responses at higher concentrations correlated with decreased cell viability. Dose-dependent increases in IL-1β, IL-1α, TNF-α and MIP-1β were observed in response to HT-AmB at concentrations up to 10 µg/mL, whereas no clear increase in MIP-1α in response to HT-AmB was observed (Table 2 ). These responses were substantially less than those observed with corresponding concentrations of AmB-DOC. No clear response to either AmB-DOC or HT-AmB was observed for IL-1Ra or MCP-1 (data not shown).
Discussion
As expected, AmB-DOC elicited dose-dependent toxicity against THP-1 cells as assessed by erythrosin B exclusion. In contrast, no effect on cell viability was noted at any concentration studied for HT-AmB. This is consistent with the findings of Gaboriau et al., 2 who reported decreased haemolysis of red blood cells by HT-AmB compared with AmB-DOC. These investigators also reported reduced toxicity to the cell line HT29 as measured by lactate dehydrogenase release and the MTT assay. Petit et al. 4 reported LD 50 values of 5 mg/kg for AmB-DOC compared with 8.1 mg/kg for HT-AmB in mice 1 week following intravenous administration. Consistent with these findings, Kwong et al. 5 demonstrated that a single intravenous dose of AmB-DOC 1 mg/kg in New Zealand white rabbits resulted in a 51.7% increase in baseline serum creatinine, whereas no change in serum creatinine was observed after administration of an equal dose of HT-AmB. To ensure that antifungal activity of amphotericin B was not compromised by heat treatment we measured the MIC and IC 50 for both AmB-DOC and HT-AmB against several Candida species. Consistent with previous reports for both C. albicans 2 and Cryptococcus neoformans, 4 we found no appreciable difference in these parameters between the two preparations.
Amphotericin B has been shown to induce the production of IL-1β and TNF-α in human and murine monocytes. 6, [8] [9] [10] Infusion-related fever, and rigors associated with amphotericin B administration are believed to be a result of the production of these cytokines. 9, 10 Other cytokines and chemokines that have been shown to be induced by amphotericin B include IL-1Ra, IL-8, MIP-1α, MIP-1β and MCP-1. 8 Whereas these molecules may contribute to amphotericin Bassociated toxicity, they may also contribute favourably to the antifungal activity of amphotericin B through their immunomodulatory actions. Consistent with the work of Hartsel et al., 3 we found amphotericin B-induced TNF-α production in THP-1 cells to be abrogated by heat treatment of amphotericin B. We also observed similar results for IL-1β, MIP-1α and MIP-1β. Concentrations of these secreted cytokines increased in a dose-dependent fashion in response to doses of AmB-DOC up to 5 µg/mL. These responses diminished in conjunction with reduced cell viability. Dose-dependent responses were also observed for HT-AmB, but at higher concentrations than those observed with AmB-DOC.
We also observed a dose-dependent response to AmB-DOC for IL-1α, but only up to a dose of 2.5 µg/mL. The diminished response observed with higher AmB-DOC doses is likely to reflect the cell-associated nature of this cytokine, where expression would be expected to more closely reflect cell viability compared with secreted cytokines. This is the first demonstration of the production of IL-1α in response to amphotericin B.
We did not observe a dose-dependent increase in IL-1Ra or MCP-1 in response to AmB-DOC after exposure to either amphotericin B preparation for 2 h. In previous studies, production of these cytokines was measured at 6 h (for MCP-1) and at 24 and 48 h (for IL-1Ra) after AmB-DOC exposure. 6, 8 In the present study, we chose to measure cytokine and chemokine concentrations at 2 h after exposure, as this reflects the period of time in which amphotericin B-associated infusionrelated toxicity is observed. 1, 9 In light of the anti-inflammatory properties of MCP-1 and IL-1Ra, it is probable that these molecules are produced to counter the initial pro-inflammatory response elicited by amphotericin B in these cells.
In conclusion, heat treatment of AmB-DOC abrogates amphotericin B-induced toxicity as well as cytokine and chemokine production in THP-1 cells, while not compromising the antifungal activity of this agent. In light of these findings, as well as previous studies demonstrating reduced toxicity with this amphotericin B preparation, heat treatment of amphotericin B may prove to be a cost-effective approach to improving the therapeutic index of this antifungal agent. 
